

Jean Michel Pawlotsky

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7537772/jean-michel-pawlotsky-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

5,041

citations

30

h-index

71

g-index

76

ext. papers

6,433

ext. citations

10.5

avg, IF

6.72

L-index

#	Paper	IF	Citations
68	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
67	New hepatitis C therapies: the toolbox, strategies, and challenges. <i>Gastroenterology</i> , 2014 , 146, 1176-92	13.3	408
66	Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. <i>Gastroenterology</i> , 2016 , 151, 70-86	13.3	402
65	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , 2020 , 369, m1844	5.9	266
64	Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. <i>Hepatology</i> , 2011 , 53, 1742-51	11.2	257
63	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , 2016 , 64, 2038-2046	11.2	242
62	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
61	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , 2014 , 147, 132-142.e4	13.3	207
60	Chronic hepatitis B virus infection. <i>Lancet, The</i> , 2018 , 392, 2313-2324	40	206
59	Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. <i>Journal of Virology</i> , 1998 , 72, 2795-805	6.6	162
58	NS5A inhibitors in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 375-82	13.4	155
57	Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. <i>Cell</i> , 2021 , 184, 1201-1213.e14	36.4	110
56	New virologic tools for management of chronic hepatitis B and C. <i>Gastroenterology</i> , 2012 , 142, 1303-1313.e1	13.3	97
55	Dynamics of hepatitis B virus resistance to lamivudine. <i>Journal of Virology</i> , 2006 , 80, 643-53	6.6	80
54	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
53	Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. <i>Journal of Virology</i> , 1999 , 73, 6490-9	6.6	71
52	Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. <i>Hepatology</i> , 2020 , 72, 2000-2013	11.2	59

51	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. <i>Hepatology</i> , 2019 , 69, 513-523	11.2	57
50	Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. <i>Hepatology</i> , 2017 , 66, 1826-1841	11.2	55
49	Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. <i>Hepatology</i> , 2016 , 63, 1809-16	11.2	51
48	Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 3641-7	9.7	50
47	Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. <i>Nature Communications</i> , 2016 , 7, 12777	17.4	44
46	Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. <i>Gastroenterology</i> , 2015 , 148, 468-79	13.3	41
45	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015 , 62, 1013-23	11.2	39
44	Virologic Tools for HCV Drug Resistance Testing. <i>Viruses</i> , 2015 , 7, 6346-59	6.2	37
43	Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	35
42	Small-Molecule Inhibitors of Cyclophilins Block Opening of the Mitochondrial Permeability Transition Pore and Protect Mice From Hepatic Ischemia/Reperfusion Injury. <i>Gastroenterology</i> , 2019 , 157, 1368-1382	13.3	33
41	Direct-acting antiviral agents and the path to interferon independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 728-37	6.9	32
40	Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. <i>Gastroenterology</i> , 2011 , 140, 755-60	13.3	31
39	COVID-19 and the liver-related deaths to come. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 523-525	24.2	30
38	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021 ,	32.3	29
37	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019 , 70, 771-787	11.2	28
36	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , 2021 , 41, 456-463	7.9	25
35	SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. <i>Intensive Care Medicine</i> , 2020 , 46, 1781-1783	14.5	22
34	Tissue damage induces a conserved stress response that initiates quiescent muscle stem cell activation. <i>Cell Stem Cell</i> , 2021 , 28, 1125-1135.e7	18	22

33	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. <i>Seminars in Liver Disease</i> , 2019 , 39, 354-368	7.3	21
32	BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	19
31	The New Aptima HCV Quant Dx Real-time TMA Assay Accurately Quantifies Hepatitis C Virus Genotype 1-6 RNA. <i>Journal of Clinical Virology</i> , 2017 , 91, 5-11	14.5	16
30	HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. <i>Antiviral Therapy</i> , 2015 , 20, 177-83	1.6	16
29	Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. <i>Journal of Biological Chemistry</i> , 2017 , 292, 12860-12873	5.4	15
28	Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2681-3	5.9	15
27	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2191-2194	11.6	14
26	The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 1211-1219	9.7	13
25	Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. <i>Journal of Clinical Virology</i> , 2020 , 129, 104481	14.5	7
24	Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. <i>PLoS Pathogens</i> , 2021 , 17, e1009416	7.6	7
23	Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7
22	Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay. <i>Journal of Clinical Virology</i> , 2017 , 92, 69-74	14.5	6
21	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.. <i>Journal of Hepatology</i> , 2022 ,	13.4	6
20	Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals		5
19	Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	4
18	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015 , 10, e0127816	3.7	3
17	Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. <i>Viruses</i> , 2021 , 13,	6.2	3
16	Microdiversity of isolates in cases of infective endocarditis: selection of non-synonymous mutations and large deletions is associated with phenotypic modifications. <i>Emerging Microbes and Infections</i> , 2021 , 10, 929-938	18.9	3

15	Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012 , 1, 58-61	2.2	2
14	Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells		2
13	Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1583-1591	6.1	2
12	A Phenyl-Pyrrolidine Derivative Reveals a Dual Inhibition Mechanism of Myocardial Mitochondrial Permeability Transition Pore, Which Is Limited by Its Myocardial Distribution. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 376, 348-357	4.7	2
11	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.. <i>EBioMedicine</i> , 2022 , 77, 103934	8.8	2
10	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.. <i>Immunity</i> , 2022 ,	32.3	2
9	Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method. <i>Journal of Medical Virology</i> , 2018 , 90, 1352-1357	19.7	1
8	Case Report: Cerebral Nocardiosis Caused by Detected by Metagenomics in an Apparently Immunocompetent Patient.. <i>Frontiers in Immunology</i> , 2022 , 13, 719124	8.4	1
7	Performance of a high-throughput, automated enzyme immunoassay for the detection of SARS-CoV-2 antigen, including in viral "variants of concern": Implications for clinical use. <i>Journal of Clinical Virology</i> , 2021 , 146, 105048	14.5	1
6	Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas HBV Test for Use on the Cobas 4800 System. <i>Microorganisms</i> , 2021 , 9,	4.9	1
5	Fatal encephalitis caused by Newcastle disease virus in a child. <i>Acta Neuropathologica</i> , 2021 , 142, 605-608	4.3	1
4	Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (Δ) in an elderly nursing home. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
3	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.. <i>JHEP Reports</i> , 2022 , 4, 100462	10.3	1
2	Prospective Comparison Between Shotgun Metagenomics and Sanger Sequencing of the 16S rRNA Gene for the Etiological Diagnosis of Infections.. <i>Frontiers in Microbiology</i> , 2022 , 13, 761873	5.7	0
1	Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots.. <i>MSphere</i> , 2022 , e0008222	5	